Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study
- DOI
- 10.1016/j.cgh.2023.09.027
- Published
- 2024-05
- Container
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.cgh.2023.09.027,
title = {Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study},
author = {Anthony Buisson and Maria Nachury and Bruno Pereira and Mathurin Fumery},
year = {2024},
journal = {Clinical Gastroenterology and Hepatology},
doi = {10.1016/j.cgh.2023.09.027},
url = {https://doi.org/10.1016/j.cgh.2023.09.027}
}RIS
TY - JOUR TI - Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study AU - Anthony Buisson AU - Maria Nachury AU - Bruno Pereira AU - Mathurin Fumery PY - 2024 JO - Clinical Gastroenterology and Hepatology DO - 10.1016/j.cgh.2023.09.027 UR - https://doi.org/10.1016/j.cgh.2023.09.027 ER -
APA
Buisson, A., Nachury, M., Pereira, B., & Fumery, M. (2024). Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.09.027
Source records
- crossref · retrieved 2026-09-27T09:39:16.407Z